Fatal Interstitial Lung Disease Associated With Erlotinib: A Case Report and Review of Literature

2015 ◽  
Author(s):  
Yan-bin Chen
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Review Of Literature

Acceleration of interstitial lung disease induced by raltitrexed

2019 ◽  
Vol 26 (5) ◽  
pp. 1241-1243 ◽  
Author(s):  
Sarah Howlett ◽  
Raminder Aul ◽  
Mark Hill ◽  
David J Pinato
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Thymidylate Synthase ◽  
Colorectal Adenocarcinoma ◽  
Preoperative Staging ◽  
Rapid Progression ◽  
Lung Function Tests ◽  
Clinical Pattern ◽  
Significant Acceleration

Introduction Raltitrexed is a folate analogue, which selectively inhibits thymidylate synthase, used in the treatment of colorectal carcinoma. Common side effects include asthenia and gastrointestinal and haematological toxicities. Case report We present the case of a 74-year-old gentleman with incidental mild interstitial lung disease on preoperative staging CT Chest who developed acute breathlessness whilst undergoing adjuvant raltitrexed treatment for a completely excised colorectal adenocarcinoma. Management and outcome Discontinuation of raltitrexed and a course of steroid therapy resulted in resolution of symptoms, mirrored by an improvement in lung function tests. Discussion The clinical pattern of rapid progression with steroid response highlights the potential for significant acceleration of interstitial lung disease by raltitrexed.

Rituximab-Induced Interstitial Lung Disease: Case Report and Literature Review

Pharmacology ◽  
2011 ◽  
Vol 87 (5-6) ◽  
pp. 318-320 ◽  
Author(s):  
Aymen Zayen ◽  
Henda Rais ◽  
Hela Rifi ◽  
Mouna Ouarda ◽  
Mehdi Afrit ◽  
...  
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Literature Review ◽  
Lung Disease ◽  
Disease Case
Sign in / Sign up

Export Citation Format

Share Document